Download Files:
Cilastatin (sodium)
$38 – $168
Products Details
Product Description
– Cilastatin sodium (MK0791 sodium) is a reversible, competitive renal dehydropeptidase I inhibitor with an IC50 of 0.1 μM. Cilastatin sodium inhibits the bacterial metallob-lactamase enzyme CphA with an IC50 of 178 μM. Cilastatin sodium is an antibacterial adjunct[1][2][3].
Web ID
– HY-A0166A
Storage Temperature
– 4°C (Powder, protect from light, stored under nitrogen)
Shipping
– Room Temperature
Applications
– COVID-19-immunoregulation
Molecular Formula
– C16H25N2NaO5S
References
– [1]S Keynan, et al. The Renal Membrane Dipeptidase (Dehydropeptidase I) Inhibitor, Cilastatin, Inhibits the Bacterial Metallo-Beta-Lactamase Enzyme CphA. Antimicrob Agents Chemother. 1995 Jul;39(7):1629-31.|[2]Blanca Humanes, et al. Protective Effects of Cilastatin Against Vancomycin-Induced Nephrotoxicity. Biomed Res Int. 2015;2015:704382.|[3]P J Petersen, et al. In Vitro and in Vivo Activities of LJC10,627, a New Carbapenem With Stability to Dehydropeptidase I. Antimicrob Agents Chemother. 1991 Jan;35(1):203-7.|[4]Keynan S, et al. The renal membrane dipeptidase (dehydropeptidase I) inhibitor, cilastatin, inhibits the bacterialmetallo-beta-lactamase enzyme CphA. Antimicrob Agents Chemother. 1995 Jul;39(7):1629-31.
CAS Number
– 81129-83-1
Molecular Weight
– 380.43
Compound Purity
– 98.84
SMILES
– O=C(O)/C(NC([C@@H]1C(C)(C)C1)=O)=C/CCCCSC[C@H](N)C(O[Na])=O
Clinical Information
– Launched
Research Area
– Infection
Solubility
– H2O : 100 mg/mL (ultrasonic)
Target
– Antibiotic;Bacterial
Isoform
– β-lactam
Pathway
– Anti-infection
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
